Our long-term research goals are to understand the injury and repair mechanisms of the immature intestine. We are specifically focused on necrotizing enterocolitis (NEC) which is a devastating disorder that predominantly effects preterm infants.
Treatment options for NEC are limited and include bowel rest and antibiotic therapy. Our lab is investigating the use of antimicrobial peptides to help prevent and treat onset of NEC.
Infants exposed to chorioamnionitis have an increased risk of developing NEC weeks after birth. Our lab is working to understand the impact of fetal exposure to maternal inflammation (FEMI) on the development of the intestine and its host defenses.
Multiple studies have shown that probiotic use can decrease the incidence of NEC. However, it remains unclear which probiotic strains are optimal, and if prebiotic use can further optimize effects. Our lab is working to answer these important gaps in knowledge.
TICON II - 2516 Stockton Boulevard, Suite 254
Sacramento, CA
4625 2nd Avenue, Research Building II, Room 1204
Sacramento, CA